Major response of PNH to an AML chemotherapy protocol

Ann Hematol. 2018 Aug;97(8):1487-1488. doi: 10.1007/s00277-018-3307-8. Epub 2018 Mar 22.

Authors

Wolfgang Füreder¹, Wolfgang R Sperr², Karoline Gleixner², Renate Thalhammer³, Ilse Schwarzinger³, Gregor Hoermann³, Christoph Kornauth⁴, Birgit Grünberger⁵, Peter Valent²

Affiliations

¹ Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. [email protected].
² Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
³ Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
⁴ Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
⁵ Department of Oncology, Landesklinikum Wr Neustadt, Neustadt, Austria.

PMID: 29568989
DOI: 10.1007/s00277-018-3307-8

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Azacitidine / administration & dosage
Blast Crisis / blood
Blast Crisis / diagnosis
Blast Crisis / drug therapy*
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Hemoglobinuria, Paroxysmal / blood
Hemoglobinuria, Paroxysmal / diagnosis
Hemoglobinuria, Paroxysmal / drug therapy*
Humans
Leukemia, Myeloid, Acute / blood
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Remission Induction

Substances

Cytarabine
Azacitidine
Daunorubicin